The U.S. Department of Justice (DOJ) has launched a significant new initiative, the healthcare self-disclosure pilot program, designed to incentivize healthcare companies to proactively report potential violations of the False Claims Act (FCA). Running until April 22, 2027, the pilot offers a more favorable resolution for companies that voluntarily come forward with previously unknown FCA exposures. This includes a reduced repayment multiple, a coordinated release from both the DOJ and the Department of Health and Human Services (HHS), and the crucial elimination of a corporate integrity agreement (CIA). However, experts caution that the program’s success hinges on a company’s ability to detect and investigate its own issues in a timely manner, especially given that whistleblowers, or relators, often alert the government first. The pilot is explicitly closed to any conduct the government is already aware of, including information received from whistleblowers.
The Carrot and the Stick: Understanding the DOJ’s New Incentive
At its core, the DOJ’s healthcare self-disclosure pilot represents a strategic gamble on the effectiveness of incentives, often referred to as "carrots," to drive corporate behavior. For companies grappling with potential False Claims Act violations, the allure of a more palatable resolution is undeniable. Under the pilot, companies that voluntarily disclose conduct the government is unaware of can expect to resolve their FCA exposure for a repayment multiple ranging from 1.25 to 1.6 times a base repayment amount. This base amount is calculated by the DOJ based on the company’s financial data, with the specific multiplier influenced by factors such as the level of senior leadership involvement in the misconduct.
Beyond the financial incentive, the pilot offers a streamlined resolution process. Companies can secure a coordinated release from both the DOJ and HHS, entities that frequently investigate and prosecute healthcare fraud. Crucially, the program aims to spare disclosing companies the imposition of a Corporate Integrity Agreement (CIA). These agreements, often lengthy and costly, require companies to implement extensive compliance programs and undergo regular monitoring and auditing by the government for several years. The absence of a CIA represents a significant reduction in administrative burden and expense.
The Whistleblower Predicament: A Race Against Time
Despite the attractive incentives, a significant hurdle for the pilot program’s widespread adoption is the pervasive role of whistleblowers in healthcare fraud enforcement. Relators, individuals who report fraud and file lawsuits on behalf of the government under the False Claims Act’s whistleblower provisions (known as qui tam actions), are the primary engine of FCA enforcement. In Fiscal Year 2025, relators filed a record 1,297 qui tam suits across all sectors, with 458 of those specifically within the healthcare industry. These whistleblower actions are instrumental in recovering government funds, reportedly accounting for approximately 80% of the DOJ’s record recoveries in FCA cases.
The critical challenge for companies considering self-disclosure lies in the confidential nature of qui tam lawsuits. These suits are filed under seal, meaning they remain secret from the defendant company for an extended period while the government investigates. This secrecy creates a precarious situation for companies: by the time a company might uncover potential misconduct through its own internal processes, a whistleblower may have already alerted the government, rendering the conduct ineligible for the pilot program. The pilot explicitly excludes any conduct the government already knows about, which naturally includes information received through whistleblower complaints or investigations initiated by government agencies.
Jose Vela Jr., a healthcare attorney at Clark Hill, articulates this challenge succinctly: "The race may begin before a healthcare organization even knows there is a problem." This sentiment underscores the inherent tension between proactive corporate disclosure and the government’s reliance on external informants.
The Crucial Role of Robust Compliance Programs
Given the realities of whistleblower-driven enforcement and the pilot’s exclusion of known conduct, the success of the DOJ’s initiative places an immense burden on the efficacy of corporate compliance programs. Experts interviewed by Corporate Compliance Insights (CCI) consistently emphasized that the benefits of the new pilot will only materialize for organizations with sophisticated systems for detecting, investigating, and escalating potential issues.
Shannon Sumner, a principal at the consultancy PYA, highlights this point: "If an organization does not have strong reporting, investigation and escalation processes, the benefits of a clearer disclosure pathway may not matter very much." A robust compliance program should enable companies to identify concerns early, conduct prompt and thorough investigations, escalate significant matters to senior leadership and the board, and implement timely corrective actions. Without these foundational elements, a company may lack the capacity to discover its own potential FCA violations before the government, or a whistleblower, does.
Jeff McSorley, a partner in Crowell & Moring’s healthcare group and a former DOJ trial counsel, anticipates that the pilot will indeed spur an increase in voluntary disclosures. However, he predicts this increase will be most pronounced among companies that are already predisposed to coming forward. This suggests that the pilot may not fundamentally alter the behavior of companies with weaker compliance cultures, but rather reward those already committed to proactive risk management.
Navigating Overlapping Liabilities: Civil vs. Criminal Exposure
A key feature of the new pilot program is its specific focus on civil False Claims Act liabilities. The DOJ announcement clarifies that potential criminal conduct must be disclosed to its newly established National Fraud Enforcement Division. While the DOJ has indicated it will streamline the process by not requiring duplicate submissions if a criminal disclosure has already been made, companies must still carefully navigate the distinction between civil and criminal exposure.
Jose Vela Jr. explains that the same conduct can trigger civil, criminal, and administrative liabilities. For instance, a physician compensation arrangement could potentially violate the Stark Law, the Anti-Kickback Statute, and the False Claims Act, and in some instances, constitute criminal fraud. The DOJ’s coordinated policies acknowledge these overlapping violations, but the onus remains on the company to accurately identify the full scope of misconduct before selecting the appropriate disclosure pathway. A mischaracterization of potential criminal conduct as purely civil could lead to the loss of more favorable treatment under criminal disclosure policies.
Shannon Sumner advises that compliance teams should not be expected to make the ultimate legal determination of criminal versus civil exposure. Their primary role is to recognize when an issue is serious enough to warrant immediate escalation to legal counsel and senior leadership. Clear protocols for escalation, information preservation, investigation, and documentation of corrective actions are essential, particularly when potential criminal conduct is suspected.
Jeff McSorley emphasizes that when conduct may give rise to both civil and criminal liability, companies must promptly investigate the facts, assess evidence of intent, and involve counsel experienced in both civil FCA matters and criminal healthcare fraud. He notes that while the DOJ Civil Fraud Section may evaluate self-disclosures similarly regardless of the disclosure channel, disclosing only under the civil pilot does not address or mitigate potential criminal liability. This highlights the critical importance of understanding the nuances of federal law and seeking expert legal guidance.
The Board’s Role in Disclosure Decisions
The pilot program’s repayment multiplier is influenced by factors including senior leadership involvement in the misconduct. This creates a potential conflict of interest when those same leaders have a significant say in the decision of whether to self-disclose. Vela points out that executives implicated in questionable conduct should not control the investigation, influence the information presented to the board, or make the disclosure decision. In such scenarios, the board or an independent committee should oversee the investigation and disclosure decision, with independent counsel potentially preserving the integrity of the process. He stresses that a company cannot credibly demonstrate accountability while allowing potentially responsible executives to control the investigation into their own actions.
Sumner reinforces the principle of independence, stating that if senior leaders may be involved, the compliance program must have a mechanism to escalate the issue without relying on those individuals. Direct access between the compliance function and the board is crucial. The board’s role is not to conduct the investigation but to ensure appropriate independent review and that management responds effectively.
McSorley adds that companies require an objective decision-making process that prioritizes legal obligations and long-term interests over individual executive interests. In cases of potential senior leader involvement, the board or an independent committee should oversee the investigation, potentially with independent counsel. He concludes that effective compliance necessitates accountability at the top, and the decision to disclose should not be based solely on potential financial penalties but also on broader exposures, including reputational damage and potential exclusion from federal healthcare programs.
Implications for Corporate Governance and Compliance Culture
The DOJ’s healthcare self-disclosure pilot program is more than just a new enforcement tool; it is a potent catalyst for examining and strengthening corporate governance and compliance cultures within the healthcare industry. The program’s success hinges on the ability of companies to proactively identify and address their own potential wrongdoing, a capability directly tied to the robustness and effectiveness of their compliance programs.
The increased emphasis on self-detection and timely disclosure under the pilot raises the stakes for internal investigations. Companies can no longer afford to conduct lengthy, drawn-out investigations before considering disclosure. The DOJ requires a full description of the conduct, supporting documentation, and quantified repayment obligations for a submission to be considered. This necessitates a rapid yet accurate investigative process.
Experts suggest that companies should not wait for every factual question to be resolved before disclosing if they believe disclosure is in their best interest. Instead, they should make the submission as complete as possible, be prepared to supplement it with additional information, and engage openly and transparently with the DOJ. The credibility of the company throughout the process is paramount, and a perception of withholding information or a lack of forthrightness can be detrimental.
The pilot program underscores a critical message from the DOJ: genuine cooperation and accountability are valued. Companies that can demonstrate a commitment to identifying and remediating their own compliance failures are likely to receive more favorable treatment. This initiative, therefore, serves as a strong incentive for healthcare organizations to invest in and continuously improve their compliance infrastructure, ensuring that their internal processes are not only designed to prevent violations but also to detect and address them swiftly and effectively when they occur. The ultimate success of the pilot will be measured not only by the number of voluntary disclosures but by the extent to which it fosters a culture of transparency and accountability throughout the healthcare sector.
